Postbiotica has signed a licensing and commercialising agreement with Candioli Pharma, a company leader in the pet-care market. The agreement foresees the exclusivity of the postbiotic ImmunoFOS® as an active ingredient to develop innovative nutraceuticals for pet healthcare.
Thanks to this partnership Postbiotica aims to expand the use of Postbiotics in pet care, consolidating its position in the market worldwide thanks to its innovative fermentative process PBTECH®.
Candioli Pharma manufactures and sells veterinary products, focusing on companion animals (pets, birds, horses) worldwide. Throughout its 130+ years of history, the company associates its name with highly innovative products for companion animals wellness. These are the company’s strengths and the reasons for its leadership in the Italian market and fast growth in several international markets.
About Postbiotica:
Postbiotica, founded in 2016, focuses its activity to develop new solutions for global wellness thanks to its innovative fermentative process PBTECH®
Postbiotica produces new microbiota-derived natural compounds to preserve immune homeostasis and treat inflammatory reactions such as allergy, dermatitis, conjunctivitis.
